Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment

Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is lower than normal for a person's age, but a higher function than that that observed in a demented person. MCI represents a transitional state between normal aging and dementia disorders, especially Alzhe...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-08, Vol.20 (17), p.4149
Main Authors: Giau, Vo Van, Bagyinszky, Eva, An, Seong Soo A
Format: Article
Language:English
Subjects:
Activities of daily living
Age
Alzheimer’s disease
Animals
Atrophy
Biomarkers
Biomarkers - blood
Biomarkers - cerebrospinal fluid
Brain - metabolism
Brain - pathology
Brain mapping
Brain research
Circulating MicroRNA
Cognitive ability
Cognitive Dysfunction - diagnosis
Cognitive Dysfunction - etiology
Cognitive Dysfunction - metabolism
Computed tomography
Dementia
Dementia disorders
diagnosis
Diagnosis, Differential
Diagnostic systems
Disease Progression
Etiology
Functional magnetic resonance imaging
Humans
Impairment
Intelligence
Magnetic resonance imaging
Medical imaging
Memory
MicroRNAs - genetics
mild cognitive impairment
Neurodegeneration
Neuroimaging
NMR
Nuclear magnetic resonance
Photon emission
Positron emission
Positron emission tomography
Prognosis
Review
Single photon emission computed tomography
Structure-function relationships
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is lower than normal for a person's age, but a higher function than that that observed in a demented person. MCI represents a transitional state between normal aging and dementia disorders, especially Alzheimer's disease (AD). Much effort has been made towards determining the prognosis of a person with MCI who will convert to AD. It is now clear that cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau and phosphorylated tau are useful for predicting the risk of progression from MCI to AD. This review highlights the advantages of the current blood-based biomarkers in MCI, and discusses some of these challenges, with an emphasis on recent studies to provide an overview of the current state of MCI.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20174149